KeyBanc Raises Valuation of Becton, Dickinson After Impressive Execution

Trending News ☀️

Becton ($NYSE:BDX), Dickinson (BD) is a medical technology company focused on improving medical care and safety by providing a wide range of medical products and services to improve the lives of patients and health care providers. Recently, KeyBanc has upgraded its valuation and execution of Becton, Dickinson, citing strong management execution as well as the company’s innovative products as reasons for the upgrade. KeyBanc noted that BD had been able to outperform their competitors in the medical device industry due to its commitment to developing cutting-edge technology and innovative offerings. The company’s success was also attributed to its focus on executing its mission of innovating healthcare, including its commitment to expanding the reach of its products through strategic partnerships across the healthcare industry. The investment firm praised Becton, Dickinson for its strong leadership, noting that it had successfully implemented its long-term growth strategy while also working towards meeting short-term objectives.

In addition, KeyBanc also highlighted BD’s ability to build relationships with healthcare providers as well as international markets, which have helped the company expand its reach and customer base. With their strategic partnerships and innovative products, BD has successfully increased their market share, making them a leader in their industry.

Stock Price

On Wednesday, BECTON (Becton, Dickinson and Company) experienced a slight increase in its stock value, opening at $255.7 and closing at $253.8, up 0.3% from its previous close of 253.0. This minor increase follows an impressive period of execution on behalf of the company, as these positive gains have been recognized by analysts at KeyBanc Capital Markets. The bank has since raised their valuation of Becton, reflecting their confidence in the company’s performance. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Becton. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Becton. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Becton. More…

Key Ratios Snapshot

Some of the financial key ratios for Becton are shown below. More…

Analysis

At GoodWhale, we have conducted a detailed analysis of BECTON’s financials. We have assigned BECTON a medium risk rating, which means that it is a safe investment for those looking to diversify their portfolio. When conducting our analysis, we detected two risk warnings within their income and balance sheets. To get a more comprehensive understanding of these warnings and the risks associated with investing in BECTON, we encourage you to register on GoodWhale.com. Our platform offers in-depth information and insights into the financials of companies. Along with this, you can also view a company’s performance history and get real-time updates on any changes that may take place. More…

Peers

Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, instruments, and supplies. The company operates in three segments: BD Medical, BD Biosciences, and BD Diagnostics. It offers a wide range of products, including syringes, needles, catheters, blood collection devices, IV administration and infusion products, safety products, and sharps disposal systems. The company competes with Penumbra Inc, Teleflex Inc, SheerVision Inc, and other medical technology companies.

– Penumbra Inc ($NYSE:PEN)

Founded in 2002, Umbra is a leading global provider of shading and decorative products. The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods. Headquartered in Toronto, Canada, Umbra employs over 1,200 people worldwide.

Umbra’s market cap is 7.01B as of 2022. The company’s Return on Equity is -2.31%.

The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods.

– Teleflex Inc ($NYSE:TFX)

Teleflex Incorporated is a diversified global provider of medical technologies designed to improve the health and quality of people’s lives. The Company provides solutions for critical care, anesthesia, surgical, urology and emergency medicine.

– SheerVision Inc ($OTCPK:SVSO)

SheerVision Inc is a US-based company that manufactures and sells ophthalmic surgical instruments and devices. The company has a market cap of 140.32k as of 2022 and a Return on Equity of -70.28%. SheerVision’s products are used by eye surgeons to correct vision problems such as nearsightedness, farsightedness, and astigmatism. The company’s products are sold through a network of distributors and retailers worldwide.

Summary

KeyBanc recently upgraded their opinion on Becton, Dickinson’s stock, citing the company’s strong valuation and execution as reasons for the move. This upgrade is further buoyed by the company’s robust fundamentals and strong financial performance. Looking at Becton’s balance sheet, the company boasts a healthy cash position and low debt levels.

Additionally, their revenue and net income have been steadily increasing over the past few years, indicating that the company is managing their financials effectively. Furthermore, the company has been successfully executing key strategic initiatives that have helped to increase their market share and profitability. The company’s business model has proven to be well-suited to the current market, and their outlook for the future looks promising. Upon considering all of these factors, KeyBanc has determined that Becton is a favorable investment opportunity and upgraded them accordingly.